About CiMaas
CiMaas is a company based in Maastricht (Netherlands) founded in 2015 by Wilfred T V Germeraad and Gerard M J Bos was acquired by 819 Capital Partners in December 2024.. CiMaas offers products and services including Adoptive NK Cell Therapy and Feeder Cell Technology. CiMaas operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Maastricht, Netherlands
- Founders Wilfred T V Germeraad, Gerard M J Bos
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$312.9 K (USD), Grant
Jan 01, 2020
-
Investors
European Union
& 1 more
-
Employee Count
Employee Count
-
Acquired by
819 Capital Partners
(Dec 02, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CiMaas
CiMaas offers a comprehensive portfolio of products and services, including Adoptive NK Cell Therapy and Feeder Cell Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy using NK cells to target and treat cancer patients effectively.
Technology for expanding and activating NK cells for clinical use.
Funding Insights of CiMaas
- Total Funding Total Funding
- Total Rounds 1
- Last Round Grant — $312,899
-
First Round
First Round
(01 Jan 2020)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Grant - CiMaas | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CiMaas
CiMaas has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and 819 Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focused on venture capital and private equity.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CiMaas
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CiMaas
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cimaas Comparisons
Competitors of CiMaas
CiMaas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
mRNA therapeutics platform is provided for multi-functional treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cimaas
Frequently Asked Questions about CiMaas
When was CiMaas founded?
CiMaas was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Where is CiMaas located?
CiMaas is headquartered in Maastricht, Netherlands. It is registered at Maastricht, Limburg, Netherlands.
Who is the current CEO of CiMaas?
Gerard M J Bos is the current CEO of CiMaas. They have also founded this company.
What does CiMaas do?
Founded in 2015 and based in Maastricht, Netherlands, focus is placed on the development of cancer immunotherapeutics within the biotechnology sector. Operations center on preclinical drug candidates, including CIM301 as a dendritic cell vaccine targeting lung cancer, CIM201 as an adoptive CAR-NK cell therapy for solid tumors, and CIM101 as an adoptive NK cell therapy for acute myeloid leukemia.
Who are the top competitors of CiMaas?
CiMaas's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does CiMaas offer?
CiMaas offers Adoptive NK Cell Therapy and Feeder Cell Technology.
Who are CiMaas's investors?
CiMaas has 2 investors. Key investors include European Union, and 819 Capital Partners.